ASTH vs EMBC: fair value comparison
Astrana Health, Inc. and Embecta Corp. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EMBC currently sits closer to the top of our discount ranking. EMBC carries the stronger quality grade.
| ASTH | EMBC | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $35.91 | $3.72 |
| 12-month range | $22.32–$49.81 | $3.29–$14.27 |
| Sector rank | #7 of 113 Healthcare | #3 of 113 Healthcare |
| Quality grade | D | C- |
| Momentum grade | — | A |
| Leverage | High | Low |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: ASTH fair value analysis · EMBC fair value analysis